Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Standard Biotools (LAB) over the last 17 years, with Q3 2025 value amounting to $539.6 million.

  • Standard Biotools' Liabilities and Shareholders Equity fell 2082.1% to $539.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 billion, marking a year-over-year decrease of 812.77%. This contributed to the annual value of $612.3 million for FY2024, which is 8954.12% up from last year.
  • According to the latest figures from Q3 2025, Standard Biotools' Liabilities and Shareholders Equity is $539.6 million, which was down 2082.1% from $557.0 million recorded in Q2 2025.
  • In the past 5 years, Standard Biotools' Liabilities and Shareholders Equity registered a high of $777.7 million during Q1 2024, and its lowest value of $271.9 million during Q1 2022.
  • Its 5-year average for Liabilities and Shareholders Equity is $448.2 million, with a median of $390.3 million in 2022.
  • Per our database at Business Quant, Standard Biotools' Liabilities and Shareholders Equity skyrocketed by 10924.49% in 2024 and then tumbled by 2546.98% in 2025.
  • Quarter analysis of 5 years shows Standard Biotools' Liabilities and Shareholders Equity stood at $275.2 million in 2021, then skyrocketed by 41.82% to $390.3 million in 2022, then decreased by 17.23% to $323.1 million in 2023, then skyrocketed by 89.54% to $612.3 million in 2024, then decreased by 11.87% to $539.6 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $539.6 million for Q3 2025, versus $557.0 million for Q2 2025 and $579.6 million for Q1 2025.